483
Eugia Pharma Specialities LimitedEugia Pharma Specialities Limited – FDA 483, Dec 14, 2018
Record Details
An FDA inspection of Aurobindo Pharma Limited - Unit IV in Hyderabad, India, revealed significant deficiencies in aseptic processing. The firm failed to establish and follow adequate procedures to prevent microbiological contamination of sterile drug products, with issues noted in environmental monitoring, smoke studies, and media fill simulations. Additionally, protective apparel was not consistently worn to protect drug products from contamination.
View Company Profile
ID · ba5f5ab2-9af9-4614-9470-b9b649b27bed
Other documents for Eugia Pharma Specialities Limited
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.